Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Inventiva ( (IVA) ) is now available.
On October 1, 2025, Inventiva announced the appointment of Andrew Obenshain as the new Chief Executive Officer, succeeding co-founder Frédéric Cren. This leadership change is part of a strategic move to support Inventiva’s growth, particularly in preparing for potential commercialization in the U.S. market for MASH. Obenshain’s global experience in drug approvals and commercialization is expected to strengthen Inventiva’s position in the MASH field and advance the development of lanifibranor, a promising oral therapy for MASH.
The most recent analyst rating on (IVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, which poses significant risks to its long-term sustainability. Despite strong technical indicators suggesting bullish momentum, the company’s negative valuation metrics and financial challenges weigh heavily on its attractiveness. The earnings call provided some optimism with strategic developments and financing, but these are overshadowed by operational and financial difficulties.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for treating metabolic dysfunction-associated steatohepatitis (MASH). The company is evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for MASH treatment. Inventiva is publicly listed on Euronext Paris and the Nasdaq Global Market.
Average Trading Volume: 46,004
Technical Sentiment Signal: Buy
Current Market Cap: $805.9M
Find detailed analytics on IVA stock on TipRanks’ Stock Analysis page.